Basic Tumor Immunology
Section edited by Cornelis J.M. Melief, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
- RESEARCH ARTICLE
Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer
Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...Journal for ImmunoTherapy of Cancer 2017 5:69Published on: 15 August 2017 - RESEARCH ARTICLE
Tumor-derived exosomes induce CD8+ T cell suppressors
The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...Journal for ImmunoTherapy of Cancer 2017 5:65Published on: 15 August 2017 - RESEARCH ARTICLE
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...Journal for ImmunoTherapy of Cancer 2017 5:63Published on: 15 August 2017 - RESEARCH ARTICLE
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...Journal for ImmunoTherapy of Cancer 2017 5:64Published on: 15 August 2017 - RESEARCH ARTICLE
GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...Journal for ImmunoTherapy of Cancer 2017 5:47Published on: 20 June 2017 - RESEARCH ARTICLE
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...Journal for ImmunoTherapy of Cancer 2017 5:51Published on: 20 June 2017 - RESEARCH ARTICLE
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...Journal for ImmunoTherapy of Cancer 2017 5:42Published on: 16 May 2017 - RESEARCH ARTICLE
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...Journal for ImmunoTherapy of Cancer 2017 5:9Published on: 21 February 2017 - RESEARCH ARTICLE
Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model
Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...Journal for ImmunoTherapy of Cancer 2016 4:96Published on: 20 December 2016 - RESEARCH ARTICLE
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases
Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...Journal for ImmunoTherapy of Cancer 2016 4:78Published on: 15 November 2016 - RESEARCH ARTICLE
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...Journal for ImmunoTherapy of Cancer 2016 4:68Published on: 18 October 2016 - RESEARCH ARTICLE
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape
Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...Journal for ImmunoTherapy of Cancer 2016 4:49Published on: 16 August 2016 - RESEARCH ARTICLE
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5
Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...Journal for ImmunoTherapy of Cancer 2016 4:33Published on: 21 June 2016 - RESEARCH ARTICLE
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...Journal for ImmunoTherapy of Cancer 2016 4:21Published on: 19 April 2016 - RESEARCH ARTICLE
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning
Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...Journal for ImmunoTherapy of Cancer 2016 4:6Published on: 16 February 2016 - RESEARCH ARTICLE
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma
A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...Journal for ImmunoTherapy of Cancer 2016 4:10Published on: 16 February 2016 - RESEARCH ARTICLE
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant
Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...Journal for ImmunoTherapy of Cancer 2016 4:11Published on: 16 February 2016 - RESEARCH ARTICLE
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...Journal for ImmunoTherapy of Cancer 2015 3:53Published on: 15 December 2015 - RESEARCH ARTICLE
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...Journal for ImmunoTherapy of Cancer 2015 3:55Published on: 15 December 2015 - RESEARCH ARTICLE
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...Journal for ImmunoTherapy of Cancer 2015 3:37Published on: 18 August 2015
.png)
No hay comentarios:
Publicar un comentario